Synonym
20-Hydroxyeicosatetraeonic acid; 20 Hydroxyeicosatetraeonic acid; 20Hydroxyeicosatetraeonic acid; 20HETE; 20 HETE; 20-HETE
IUPAC/Chemical Name
(5Z,8Z,11Z,14Z)-20-Hydroxyicosa-5,8,11,14-tetraenoic acid
InChi Key
NNDIXBJHNLFJJP-DTLRTWKJSA-N
InChi Code
InChI=1S/C20H32O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h1,3-4,6-7,9-10,12,21H,2,5,8,11,13-19H2,(H,22,23)/b3-1-,6-4-,9-7-,12-10-
SMILES Code
OCCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(O)=O
Appearance
A solution in ethanol (100ug/ml)
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
320.47
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lu L, Wang M, Wei X, Li W. 20-HETE Inhibition by HET0016 Decreases the Blood-Brain Barrier Permeability and Brain Edema After Traumatic Brain Injury. Front Aging Neurosci. 2018 Jul 16;10:207. doi: 10.3389/fnagi.2018.00207. eCollection 2018. Erratum in: Front Aging Neurosci. 2018 Aug 20;10:239. PubMed PMID: 30061822; PubMed Central PMCID: PMC6054934.
2: Rocic P, Schwartzman ML. 20-HETE in the regulation of vascular and cardiac function. Pharmacol Ther. 2018 Jul 23. pii: S0163-7258(18)30123-2. doi: 10.1016/j.pharmthera.2018.07.004. [Epub ahead of print] Review. PubMed PMID: 30048707.
3: Zhang X, El Demerdash N, Falck JR, Munnuri S, Koehler RC, Yang ZJ. The contribution of TRPV1 channel to 20-HETE-Aggravated ischemic neuronal injury. Prostaglandins Other Lipid Mediat. 2018 Jul;137:63-68. doi: 10.1016/j.prostaglandins.2018.07.001. Epub 2018 Jul 6. Review. PubMed PMID: 30041768; PubMed Central PMCID: PMC6092952.
4: Zhang C, Booz GW, Yu Q, He X, Wang S, Fan F. Conflicting roles of 20-HETE in hypertension and renal end organ damage. Eur J Pharmacol. 2018 Aug 15;833:190-200. doi: 10.1016/j.ejphar.2018.06.010. Epub 2018 Jun 7. Review. PubMed PMID: 29886242; PubMed Central PMCID: PMC6057804.
5: Costa TJ, Ceravolo GS, Echem C, Hashimoto CM, Costa BP, Santos-Eichler RA, Oliveira MA, Jiménez-Altayó F, Akamine EH, Dantas AP, Carvalho MHC. Detrimental Effects of Testosterone Addition to Estrogen Therapy Involve Cytochrome P-450-Induced 20-HETE Synthesis in Aorta of Ovariectomized Spontaneously Hypertensive Rat (SHR), a Model of Postmenopausal Hypertension. Front Physiol. 2018 May 8;9:490. doi: 10.3389/fphys.2018.00490. eCollection 2018. PubMed PMID: 29867542; PubMed Central PMCID: PMC5952044.
6: Roman RJ, Fan F. 20-HETE: Hypertension and Beyond. Hypertension. 2018 Jul;72(1):12-18. doi: 10.1161/HYPERTENSIONAHA.118.10269. Epub 2018 May 14. Review. PubMed PMID: 29760152; PubMed Central PMCID: PMC6002933.
